* Kezar Life Sciences Inc reported a quarterly adjusted loss of $2.78 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-3.20. The mean expectation of six analysts for the quarter was for a loss of $3.15 per share. Wall Street expected results to range from $-3.80 to $-2.30 per share.
* Reported revenue was zero; analysts expected $800.00 thousand.
* Kezar Life Sciences Inc's reported EPS for the quarter was a loss of $2.78.
* The company reported a quarterly loss of $20.31 million.
* Kezar Life Sciences Inc shares had fallen by 3.1% this quarter and lost 20.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 1.6% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Kezar Life Sciences Inc is 19.00 This summary was machine generated from LSEG data November 13 at 02:20 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -3.15 -2.78 Beat
Jun. 30 2024 -3.20 -2.70 Beat
Mar. 31 2024 -3.33 -3.00 Beat
Dec. 31 2023 -3.80 -4.40 Missed
Comments